BG
VRTX icon

Bollard Group’s Vertex Pharmaceuticals VRTX Stock Holding History

Bollard Group’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1K Buy
+3
New +$1.33K ﹤0.01% 304
2023
Q3 		– Sell
-20
Closed -$7K – 649
2023
Q2 		$7K Buy
+20
New +$6.74K ﹤0.01% 356
2013
Q4 		– Sell
-1,280
Closed -$97K – 262
2013
Q3 		$97K Buy
+1,280
New +$102K 0.01% 204

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Bollard Group's VRTX Position: Q2 2026 in Review

Bollard Group opened a new position in Vertex Pharmaceuticals (VRTX) in Q2 2026: 3 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #304 among its holdings. This is a return to the name: Bollard Group previously reported a position in VRTX as recently as Q2 2023.

Bollard Group first reported a position in VRTX in Q3 2013 and has held it in 3 quarters since. The position peaked at $97K in Q3 2013. 1,761 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • Bollard Group held 3 shares of Vertex Pharmaceuticals worth $1K as of Q2 2026.
  • Vertex Pharmaceuticals was a new Bollard Group position in Q2 2026.
  • Vertex Pharmaceuticals made up ﹤0.01% of Bollard Group's portfolio in Q2 2026, its #304 holding.
  • Bollard Group first reported a position in Vertex Pharmaceuticals in Q3 2013 and has held it in 3 quarters since.
  • Bollard Group's Vertex Pharmaceuticals position peaked at $97K in Q3 2013.
  • 1,761 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on Bollard Group's 13F filing for Q2 2026, filed 12 Aug 2026.